| Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity L Corrales, LH Glickman, SM McWhirter, DB Kanne, KE Sivick, ... Cell reports 11 (7), 1018-1030, 2015 | 1365 | 2015 |
| STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade J Fu, DB Kanne, M Leong, LH Glickman, SM McWhirter, E Lemmens, ... Science translational medicine 7 (283), 283ra52-283ra52, 2015 | 755 | 2015 |
| Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity KE Sivick, AL Desbien, LH Glickman, GL Reiner, L Corrales, NH Surh, ... Cell reports 25 (11), 3074-3085. e5, 2018 | 340 | 2018 |
| TLR signaling is required for Salmonella typhimurium virulence N Arpaia, J Godec, L Lau, KE Sivick, LM McLaughlin, MB Jones, ... Cell 144 (5), 675-688, 2011 | 299 | 2011 |
| Waging War against Uropathogenic Escherichia coli: Winning Back the Urinary Tract KE Sivick, HLT Mobley Infection and immunity 78 (2), 568-585, 2010 | 292 | 2010 |
| Mucosal immunization with iron receptor antigens protects against urinary tract infection CJ Alteri, EC Hagan, KE Sivick, SN Smith, HLT Mobley PLoS pathogens 5 (9), e1000586, 2009 | 212 | 2009 |
| The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection KE Sivick, MA Schaller, SN Smith, HLT Mobley The journal of immunology 184 (4), 2065-2075, 2010 | 172 | 2010 |
| Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity GT Crimmins, AA Herskovits, K Rehder, KE Sivick, P Lauer, ... Proceedings of the National Academy of Sciences 105 (29), 10191-10196, 2008 | 134 | 2008 |
| STING-activating adjuvants elicit a Th17 immune response and protect against Mycobacterium tuberculosis infection E Van Dis, KM Sogi, CS Rae, KE Sivick, NH Surh, ML Leong, DB Kanne, ... Cell reports 23 (5), 1435-1447, 2018 | 118 | 2018 |
| Protease Activity, Secretion, Cell Entry, Cytotoxicity, and Cellular Targets of Secreted Autotransporter Toxin of Uropathogenic Escherichia coli NM Maroncle, KE Sivick, R Brady, FE Stokes, HLT Mobley Infection and immunity 74 (11), 6124-6134, 2006 | 94 | 2006 |
| TNFα and radioresistant stromal cells are essential for therapeutic efficacy of cyclic dinucleotide STING agonists in nonimmunogenic tumors BJ Francica, A Ghasemzadeh, AL Desbien, D Theodros, KE Sivick, ... Cancer immunology research 6 (4), 422-433, 2018 | 80 | 2018 |
| Toll-like receptor-deficient mice reveal how innate immune signaling influences Salmonella virulence strategies KE Sivick, N Arpaia, GL Reiner, BL Lee, BR Russell, GM Barton Cell host & microbe 15 (2), 203-213, 2014 | 47 | 2014 |
| Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity KE Sivick, AL Desbien, LH Glickman, GL Reiner, L Corrales, NH Surh, ... Cell Reports 29 (3), 785-789, 2019 | 32 | 2019 |
| An “omics” approach to uropathogenic Escherichia coli vaccinology KE Sivick, HLT Mobley Trends in microbiology 17 (10), 431-432, 2009 | 28 | 2009 |
| Cyclic Dinucleotide–Adjuvanted Dengue Virus Nonstructural Protein 1 Induces Protective Antibody and T Cell Responses DA Espinosa, PR Beatty, GL Reiner, KE Sivick, L Hix Glickman, ... The Journal of Immunology 202 (4), 1153-1162, 2019 | 26 | 2019 |
| Targeting CD73 with AB680 (Quemliclustat), a novel and potent small-molecule CD73 inhibitor, restores immune functionality and facilitates antitumor immunity D Piovesan, JBL Tan, A Becker, J Banuelos, N Narasappa, D DiRenzo, ... Molecular Cancer Therapeutics 21 (6), 948-959, 2022 | 20 | 2022 |
| Comment on “The common R71H-G230A-R293Q human TMEM173 is a null allele” KE Sivick, NH Surh, AL Desbien, EP Grewal, GE Katibah, SM McWhirter, ... The Journal of Immunology 198 (11), 4183-4185, 2017 | 19 | 2017 |
| Activation of human STING by a molecular glue-like compound J Li, SM Canham, H Wu, M Henault, L Chen, G Liu, Y Chen, G Yu, ... Nature chemical biology 20 (3), 365-372, 2024 | 9 | 2024 |
| Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity L Corrales, LH Glickman, SM McWhirter, DB Kanne, KE Sivick, ... Journal for ImmunoTherapy of Cancer 2, 1-1, 2014 | 8 | 2014 |
| TLR signaling is required for virulence of an intracellular pathogen N Arpaia, J Godec, L Lau, KE Sivick, LM McLaughlin, MB Jones, ... Cell 144 (5), 675, 2011 | 7 | 2011 |
